BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33030312)

  • 1. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
    Smith JA; Beacroft L; Abdullah F; Buthelezi B; Makua M; Morroni C; Ramjee G; Velasquez C; Hallett TB
    J Int AIDS Soc; 2020 Oct; 23(10):e25620. PubMed ID: 33030312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What impact could DMPA use have had in South Africa and how might its continued use affect the future of the HIV epidemic?
    Beacroft L; Smith JA; Hallett TB
    J Int AIDS Soc; 2019 Nov; 22(11):e25414. PubMed ID: 31729195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.
    Hapgood JP
    AIDS Res Hum Retroviruses; 2020 May; 36(5):357-366. PubMed ID: 31797677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
    Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
    Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies.
    Jain AK
    Contraception; 2012 Dec; 86(6):645-52. PubMed ID: 22541635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
    Dragoman MV; Gaffield ME
    Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda.
    Grabowski MK; Gray RH; Makumbi F; Kagaayi J; Redd AD; Kigozi G; Reynolds SJ; Nalugoda F; Lutalo T; Wawer MJ; Serwadda D; Quinn TC; Tobian AAR
    Lancet Glob Health; 2015 Aug; 3(8):e478-e486. PubMed ID: 26094162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
    Hofmeyr GJ; Singata-Madliki M; Batting J; Steyn P; Thomas KK; Issema R; Beesham I; Mbatsane E; Morrison C; Deese J; Smit J; Philip N; Palanee-Phillips T; Reddy K; Onono M; Mastro TD; Baeten JM;
    PLoS One; 2024; 19(5):e0299802. PubMed ID: 38722832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.
    Morrison CS; Chen PL; Kwok C; Baeten JM; Brown J; Crook AM; Van Damme L; Delany-Moretlwe S; Francis SC; Friedland BA; Hayes RJ; Heffron R; Kapiga S; Karim QA; Karpoff S; Kaul R; McClelland RS; McCormack S; McGrath N; Myer L; Rees H; van der Straten A; Watson-Jones D; van de Wijgert JH; Stalter R; Low N
    PLoS Med; 2015 Jan; 12(1):e1001778. PubMed ID: 25612136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
    Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
    Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.
    Zalenskaya IA; Chandra N; Yousefieh N; Fang X; Adedipe OE; Jackson SS; Anderson SM; Mauck CK; Schwartz JL; Thurman AR; Doncel GF
    J Clin Invest; 2018 Oct; 128(10):4622-4638. PubMed ID: 30222141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
    Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
    Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
    AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.
    Heffron R; Parikh UM; Penrose KJ; Mugo N; Donnell D; Celum C; Mellors JW; Baeten JM;
    AIDS Behav; 2017 Jul; 21(7):2173-2179. PubMed ID: 27699594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal contraceptive use and discontinuation among HIV-infected women in Uganda and Zimbabwe.
    Bengtson A; Kwok C; Salata RA; Byamugisha J; Chipato T; Rwambuya S; Moyo P; Morrison CS
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):506-13. PubMed ID: 23572011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.
    Hofmeyr GJ; Singata-Madliki M; Lawrie TA; Bergel E; Temmerman M
    Reprod Health; 2016 Apr; 13():42. PubMed ID: 27091008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada.
    Socías ME; Duff P; Shoveller J; Montaner JSG; Nguyen P; Ogilvie G; Shannon K
    Sex Transm Infect; 2017 Jun; 93(4):284-289. PubMed ID: 27821613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.